These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 33153943)

  • 21. Pharmacoeconomics of medical abortion: a review of cost in the United States, Europe and Asia.
    Murthy A; Creinin MD
    Expert Opin Pharmacother; 2003 Apr; 4(4):503-13. PubMed ID: 12667113
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of approval of home use of misoprostol in England on access to medical abortion: An interrupted time series analysis.
    Lewandowska M; Carter DJ; Gasparrini A; Lohr PA; Wellings K
    Int J Gynaecol Obstet; 2024 Jan; 164(1):286-297. PubMed ID: 37621171
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized trial of misoprostol and cervagem in combination with a reduced dose of mifepristone for induction of abortion.
    Baird DT; Sukcharoen N; Thong KJ
    Hum Reprod; 1995 Jun; 10(6):1521-7. PubMed ID: 7593528
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk factors for unsuccessful medical abortion with mifepristone and misoprostol.
    Haimov-Kochman R; Arbel R; Sciaky-Tamir Y; Brzezinski A; Laufer N; Yagel S
    Acta Obstet Gynecol Scand; 2007; 86(4):462-6. PubMed ID: 17486469
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acceptability of suction curettage and mifepristone abortion in the United States: a prospective comparison study.
    Jensen JT; Harvey SM; Beckman LJ
    Am J Obstet Gynecol; 2000 Jun; 182(6):1292-9. PubMed ID: 10871441
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early abortion in Ontario: options and costs.
    Limacher JJ; Daniel I; Isaacksz S; Payne GJ; Dunn S; Coyte PC; Laporte A
    J Obstet Gynaecol Can; 2006 Feb; 28(2):142-8. PubMed ID: 16643717
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Consistency of medical abortion efficacy from 5 through 14 weeks' gestation.
    Garbin O; Vayssiere C; Bettahar-Lebugle K; Nisand I
    Eur J Obstet Gynecol Reprod Biol; 2006 Nov; 129(1):36-40. PubMed ID: 16325992
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Changes in the numbers of hospital-based abortions and outpatient early medical abortions in Victoria, 2012-22: a retrospective cohort study.
    Marzan MB; Johnson E; Moore P; Jiang H; Hui L
    Med J Aust; 2024 Feb; 220(3):145-153. PubMed ID: 38305486
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Medical termination for pregnancy in early first trimester (≤ 63 days) using combination of mifepristone and misoprostol or misoprostol alone: a systematic review.
    Abubeker FA; Lavelanet A; Rodriguez MI; Kim C
    BMC Womens Health; 2020 Jul; 20(1):142. PubMed ID: 32635921
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early medical abortion using low-dose mifepristone followed by buccal misoprostol: a large Australian observational study.
    Goldstone P; Michelson J; Williamson E
    Med J Aust; 2012 Sep; 197(5):282-6. PubMed ID: 22938126
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A cost-effectiveness analysis of surgical versus medical management of early pregnancy loss.
    Rausch M; Lorch S; Chung K; Frederick M; Zhang J; Barnhart K
    Fertil Steril; 2012 Feb; 97(2):355-60. PubMed ID: 22192348
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The efficacy and acceptability of mifepristone medical abortion with home administration misoprostol provided by private providers linked with the hospital: a prospective study of 433 patients].
    Faucher P; Baunot N; Madelenat P
    Gynecol Obstet Fertil; 2005 Apr; 33(4):220-7. PubMed ID: 15894206
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cervical preparation prior to surgical abortion in real-life conditions and factors driving the prescription: A national observational study.
    David P; Rondeau V; Pouriel M; Agostini A
    J Gynecol Obstet Hum Reprod; 2017 Dec; 46(10):715-719. PubMed ID: 29038033
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early abortion. Update and implications for midwifery practice.
    Narrigan D
    J Nurse Midwifery; 1998; 43(6):492-501. PubMed ID: 9871382
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mifepristone and misoprostol is safe and effective method in the second-trimester pregnancy termination.
    Nissi R; Santala M; Immonen E; Talvensaari-Mattila A
    Arch Gynecol Obstet; 2016 Nov; 294(6):1243-1247. PubMed ID: 27522599
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of medical abortion using mifepristone and buccal misoprostol through 63 days.
    Gatter M; Cleland K; Nucatola DL
    Contraception; 2015 Apr; 91(4):269-73. PubMed ID: 25592080
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Medical Abortion Provided by Nurse-Midwives or Physicians in a High Resource Setting: A Cost-Effectiveness Analysis.
    Sjöström S; Kopp Kallner H; Simeonova E; Madestam A; Gemzell-Danielsson K
    PLoS One; 2016; 11(6):e0158645. PubMed ID: 27362270
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current and potential methods for second trimester abortion.
    Lerma K; Blumenthal PD
    Best Pract Res Clin Obstet Gynaecol; 2020 Feb; 63():24-36. PubMed ID: 31281014
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness of self-managed medication abortion between 13 and 24 weeks gestation: A retrospective review of case records from accompaniment groups in Argentina, Chile, and Ecuador.
    Moseson H; Bullard KA; Cisternas C; Grosso B; Vera V; Gerdts C
    Contraception; 2020 Aug; 102(2):91-98. PubMed ID: 32360817
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vaginal misoprostol administered 1, 2, or 3 days after mifepristone for early medical abortion: A randomized trial.
    Schaff EA; Fielding SL; Westhoff C; Ellertson C; Eisinger SH; Stadalius LS; Fuller L
    JAMA; 2000 Oct; 284(15):1948-53. PubMed ID: 11035891
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.